Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.51 USD +2.03% Intraday chart for Karyopharm Therapeutics Inc. +6.34% +74.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Transcript : Karyopharm Therapeutics Inc., Q4 2023 Earnings Call, Feb 29, 2024
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024 CI
North American Morning Briefing : Fed's Preferred -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Karyopharm Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023 CI
Karyopharm Therapeutics Inc.(NasdaqGS:KPTI) dropped from NASDAQ Biotechnology Index CI
Karyopharm Therapeutics Says Phase 1 Study of Myelofibrosis Treatment Showed Spleen Volume Reduction Durability MT
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients CI
Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors CI
RBC Cuts Price Target on Karyopharm Therapeutics to $3 From $4, Keeps Outperform Rating MT
Wedbush Trims Karyopharm Therapeutics' PT to $3 From $4, Sees Limited Upside Near Term; Maintains Neutral Rating MT
Karyopharm Therapeutics Inc. Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition CI
Transcript : Karyopharm Therapeutics Inc., Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q3 Revenue $36M, vs. Street Est of $37.4M MT
Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023 CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Karyopharm, Bristol-Myers Squibb to Assess Mezigdomide With Selinexor for Relapsed, Refractory Multiple Myeloma MT
Karyopharm Therapeutics Inc. Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD?? Agent CC-92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma CI
Transcript : Karyopharm Therapeutics Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 05:30 PM
Transcript : Karyopharm Therapeutics Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023 12:30 PM
Chart Karyopharm Therapeutics Inc.
More charts
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.51 USD
Average target price
5.571 USD
Spread / Average Target
+268.97%
Consensus
  1. Stock
  2. Equities
  3. Stock Karyopharm Therapeutics Inc. - Nasdaq
  4. News Karyopharm Therapeutics Inc.
  5. RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Sector Perform Rating